Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cardiac Marker Testing Market, by Disease
1.4.2 North America Cardiac Marker Testing Market, by End User
1.4.3 North America Cardiac Marker Testing Market, by Product
1.4.4 North America Cardiac Marker Testing Market, by Biomarker Type
1.4.5 North America Cardiac Marker Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trails & Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. North America Cardiac Marker Testing Market by Disease
4.1 North America Myocardial Infarction Market by Country
4.2 North America Congestive Heart Failure Market by Country
4.3 North America Atherosclerosis Market by Country
4.4 North America Acute Coronary Syndrome Market by Country
4.5 North America Ischemia Market by Country
Chapter 5. North America Cardiac Marker Testing Market by End User
5.1 North America Laboratory Testing Facilities Market by Country
5.2 North America Point-of-Care Testing Facilities Market by Country
5.3 North America Academic Institutions Market by Country
Chapter 6. North America Cardiac Marker Testing Market by Product
6.1 North America Reagents & Kits Market by Country
6.2 North America Instruments Market by Country
Chapter 7. North America Cardiac Marker Testing Market by Biomarker Type
7.1 North America Troponin I & T Market by Country
7.2 North America Creatine kinase-MB(CK-MB) Market by Country
7.3 North America Natriuretic peptide (Bnp Or Nt-Probnp) Market by Country
7.4 North America Myoglobin Market by Country
7.5 North America High-sensitivity C-reactive protein(hs-CRP) Market by Country
7.6 North America Others Market by Country
Chapter 8. North America Cardiac Marker Testing Market by Country
8.1 US Cardiac Marker Testing Market
8.1.1 US Cardiac Marker Testing Market by Disease
8.1.2 US Cardiac Marker Testing Market by End User
8.1.3 US Cardiac Marker Testing Market by Product
8.1.4 US Cardiac Marker Testing Market by Biomarker Type
8.2 Canada Cardiac Marker Testing Market
8.2.1 Canada Cardiac Marker Testing Market by Disease
8.2.2 Canada Cardiac Marker Testing Market by End User
8.2.3 Canada Cardiac Marker Testing Market by Product
8.2.4 Canada Cardiac Marker Testing Market by Biomarker Type
8.3 Mexico Cardiac Marker Testing Market
8.3.1 Mexico Cardiac Marker Testing Market by Disease
8.3.2 Mexico Cardiac Marker Testing Market by End User
8.3.3 Mexico Cardiac Marker Testing Market by Product
8.3.4 Mexico Cardiac Marker Testing Market by Biomarker Type
8.4 Rest of North America Cardiac Marker Testing Market
8.4.1 Rest of North America Cardiac Marker Testing Market by Disease
8.4.2 Rest of North America Cardiac Marker Testing Market by End User
8.4.3 Rest of North America Cardiac Marker Testing Market by Product
8.4.4 Rest of North America Cardiac Marker Testing Market by Biomarker Type
Chapter 9. Company Profiles
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Product Launches and Product Expansions:
9.1.5.2 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Siemens Healthineers AG (Siemens AG)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.5.3 Acquisition and Mergers:
9.2.6 SWOT Analysis
9.3 Becton, Dickinson and Company
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 F. Hoffmann-La Roche Ltd.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Product Launches and Product Expansions:
9.5 Thermo Fisher Scientific, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.5.2 Acquisition and Mergers:
9.6 Bio-Rad laboratories, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Acquisition and Mergers:
9.7 Danaher Corporation
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.8 DiaSorin S.p.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.9 PerkinElmer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Product Launches and Product Expansions:
9.10. BioMérieux S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 